Home » Pharmaceutical Cost Cutting Still Includes R&D for Some

Pharmaceutical Cost Cutting Still Includes R&D for Some

November 7, 2013

Fitch Rulings believes that brand pharmaceutical companies such as Pfizer, Merck and Bristol-Myers Squibb are in for more rounds of cost-cutting measures in the near future.
India InfoLine

27Jan
Medical Device Clinical Trials in China: Latest Regulatory Developments
27Jan
FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations
09Feb
Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19
10Feb
FDA Under the Biden Administration: What’s to Come and What It Will Mean
11Feb
Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era
17Feb
Effective Auditing for Manufacturing Quality

Pharmaceutical Cost Cutting Still Includes R&D for Some

Upcoming Events

Medical Device Clinical Trials in China: Latest Regulatory Developments

FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

FDA Under the Biden Administration: What’s to Come and What It Will Mean

Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

Effective Auditing for Manufacturing Quality

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

Regeneron’s Antibody Cocktail Shows Efficacy as COVID-19 Treatment

FDA to Review Berkshire’s 510(k) Submission for Remote Drug-Delivery System

Desidustat Improves Oxygenation for Hospitalized COVID-19 Patients

Abbott’s Panbio COVID-19 Test Gets Additional CE Marks

The Revised ICH E8: A Guide to New Clinical Trial Requirements